Toward More Tailored Dosing Strategies While the panacea of individualised dosing regimens might represent a leap too far in terms of complexity, the opportunity does exist for pharmaceutical companies to implement a more tailored approach when it comes to dosing, arriving at a more delicate balance of drug exposure, bioavailability, efficacy and safety based on the characteristics of certain patient cohorts
Currently, the specific second messengers involved in the CCK signaling pathway from the NTS to hypothalamic regions remain unclear
GLP-1 agonists are some of the most powerful medicines for weight management that we have to offer, says Raoul Manalac, MD , Senior Director of Clinical Experience for Metabolic Health at Ro
10.7150/jca.16584 85 KimH
If you also take the blood thinner warfarin, you may have a higher risk of uncontrolled bleeding
Novo Nordisk (Denmark): Novo, as described above, dominates the GLP-1 market with products like Wegovy and Ozempic